Searchable abstracts of presentations at key conferences in endocrinology

ea0034p374 | Steroids | SFEBES2014

Differential impact of PAPS synthases on human sulfation pathways

Mueller Jonathan W , Idkowiak Jan , House Philip J , McNelis Joane , Rose Ian I , van den Boom Johannes , Schlereth Florian , Dhir Vivek , Arlt Wiebke

Mutations in the gene for 3′-phospho-adenosine-5′-phosphosulfate synthase 2 (PAPSS2) are linked to bone and cartilage mal-formation. More recently, we could identify PAPSS2-mutations as mono-genetic cause for androgen excess in women due to apparent SULT2A1 deficiency, the enzyme responsible for sulfation of the testosterone precursor DHEA that relies on PAPS provision by PAPS synthases. The only human orthologue, PAPSS1, is expressed in the affected tissu...

ea0050oc1.4 | Early Career Oral Communications | SFEBES2017

An investigation into sodium-iodide symporter (NIS) dimerization and its impact on radioiodide uptake in thyroid cancer

Thompson Rebecca J. , Fletcher Alice , Nieto Hannah , Alshahrani Mohammed , Baker Katie , Mueller Jonathan W. , Fine Nicholas H.F. , Hodson David J. , Read Martin L. , Boelaert Kristien , Smith Vicki E. , McCabe Christopher J.

The ability of the thyroid to accumulate iodide via the sodium-iodide symporter (NIS) can be utilised to successfully treat the majority of thyroid cancers with radioiodide. However, approximately 25% of thyroid cancers lose this functional NIS activity and become unresponsive to radioiodide therapy, resulting in a poorer prognosis. Our knowledge of NIS regulation is limited, but as dimerisation of NIS has been proposed, we sought to investigate NIS dimerisation and its impact...

ea0050oc1.4 | Early Career Oral Communications | SFEBES2017

An investigation into sodium-iodide symporter (NIS) dimerization and its impact on radioiodide uptake in thyroid cancer

Thompson Rebecca J. , Fletcher Alice , Nieto Hannah , Alshahrani Mohammed , Baker Katie , Mueller Jonathan W. , Fine Nicholas H.F. , Hodson David J. , Read Martin L. , Boelaert Kristien , Smith Vicki E. , McCabe Christopher J.

The ability of the thyroid to accumulate iodide via the sodium-iodide symporter (NIS) can be utilised to successfully treat the majority of thyroid cancers with radioiodide. However, approximately 25% of thyroid cancers lose this functional NIS activity and become unresponsive to radioiodide therapy, resulting in a poorer prognosis. Our knowledge of NIS regulation is limited, but as dimerisation of NIS has been proposed, we sought to investigate NIS dimerisation and its impact...